Jacobs Levy Equity Management, Inc Durect Corp Transaction History

Jacobs Levy Equity Management, Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$1.86 - $2.87 $79,358 - $122,451	-42,666 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$1.65 - $2.43 $19,687 - $28,994	11,932 Added 38.82%	42,666 $88,000
Q3 2020 Nov 16, 2020	BUY	$1.6 - $2.35 $49,174 - $72,224	30,734 New	30,734 $53,000
Q2 2019 Aug 13, 2019	SELL	$0.51 - $0.86 $130,977 - $220,863	-256,818 Closed	0 $0
Q1 2019 May 14, 2019	SELL	$0.51 - $0.82 $64,339 - $103,447	-126,156 Reduced 32.94%	256,818 $161,000
Q4 2018 Feb 14, 2019	SELL	$0.48 - $1.1 $4,159 - $9,532	-8,666 Reduced 2.21%	382,974 $185,000
Q3 2018 Nov 14, 2018	BUY	$1.06 - $1.69 $78,652 - $125,398	74,200 Added 23.37%	391,640 $431,000
Q2 2018 Aug 14, 2018	BUY	$1.56 - $2.51 $79,218 - $127,460	50,781 Added 19.04%	317,440 $495,000
Q1 2018 May 15, 2018	BUY	$0.91 - $2.24 $72,975 - $179,632	80,193 Added 43.01%	266,659 $571,000
Q4 2017 Feb 13, 2018	BUY	$0.78 - $2.1 $104,112 - $280,301	133,477 Added 251.9%	186,466 $172,000
Q3 2017 Nov 14, 2017	BUY	$1.55 - $1.82 $82,132 - $96,439	52,989	52,989 $94,000

593K

Ticker DRRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 227,794,000
Market Cap $175M
Description
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogeno...

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.